Phila Department Public Health

The Philadelphia Department of Public Health Division of HIV Health is a municipal government entity operating within Philadelphia's public health infrastructure that serves as a prime recipient of federal grant awards from the Centers for Disease Control and Prevention. As a local government division focused specifically on HIV health initiatives, the organization functions as the city's primary public health authority responsible for implementing comprehensive disease prevention, surveillance, and community health programs targeting high-risk populations across the Philadelphia metropolitan area. The division maintains active federal grant programs focused on HIV prevention, treatment linkage, and surveillance activities designed to reduce new infections and health disparities among vulnerable populations.

The division has received three significant federal cooperative agreements from the CDC's National Center for HIV/AIDS that collectively demonstrate its extensive work in HIV prevention and epidemiological surveillance. Under the CFDA 93.940 program, the division secured a $579,853 five-year Cooperative Agreement effective September 30, 2025, which supports comprehensive HIV and tuberculosis prevention efforts including targeted testing, treatment initiation, contact investigation, and community engagement strategies, with specific focus on pre-exposure prophylaxis delivery, syringe service programs, and interventions targeting men who have sex with men, people who inject drugs, and transgender individuals. A second cooperative agreement awarded August 1, 2024, extends through May 31, 2029, and addresses high-impact HIV prevention and surveillance programs emphasizing health equity, syndemic approaches, linkage to care, and viral suppression across Philadelphia's nearly 19,000 diagnosed HIV population. Additionally, the division operates the National HIV Behavioral Surveillance program, a bio-behavioral surveillance system that has been continuously funded through a January 1, 2022 cooperative agreement extending through December 31, 2026, which monitors HIV prevalence and risk behaviors among key populations including men who have sex with men, injection drug users, heterosexuals at increased risk, and transgender persons through anonymous cross-sectional surveys and voluntary HIV testing initiatives.